Main cancers (summary list)

Five-year relative survival by diagnosis year

Five-year relative survival (with 95% confidence interval)

EUROCARE-4

Cancer type

Sex

Age at diagnosis

1994-97

1998-2002

2003-2007

2007-2009

##2000-2002

(EUROCARE definition)

cohort

*hybrid

Ireland

Europe average

all except NMSC'

both

all 15-99

45.7%

51.8%

59.5%

60.2%

(ICD10 C00-C97 ex C44)

(unstandardized)

(45.1-46.2%)

(51.3-52.2%)

(58.9-60%)

(59.6-60.7%)

all except NMSC

both

all 15-99

44.0%

49.6%

56.4%

57.0%

(ICD10 C00-C97 ex C44)

(age-standardized)#

(42.8-45.1%)

(48.6-50.5%)

(55.3-57.4%)

(55.8-58.0%)

all except NMSC

male

all 15-99

39.9%

48.1%

58.5%

59.2%

(ICD10 C00-C97 ex C44)

(unstandardized)

(39.1-40.6%)

(47.4-48.7%)

(57.7-59.2%)

(58.4-59.9%)

all except NMSC

male

all 15-99

39.6%

47.1%

56.6%

57.4%

48.1%

47.3%

(ICD10 C00-C97 ex C44)

(age-standardized)#

(37.9-41.1%)

(45.7-48.4%)

(55.0-58.1%)

(55.7-59.0%)

(47.2-49.0%)

(46.8-47.8%)

all except NMSC

female

all 15-99

51.2%

55.4%

60.5%

61.1%

(ICD10 C00-C97 ex C44)

(unstandardized)

(50.4-51.9%)

(54.7-56.0%)

(59.7-61.2%)

(60.3-61.9%)

all except NMSC

female

all 15-99

47.8%

51.4%

55.5%

55.8%

51.9%

55.8%

(ICD10 C00-C97 ex C44)

(age-standardized)#

(46.2-49.3%)

(50.0-52.6%)

(54-56.9%)

(54.2-57.4%)

(51.0-52.8%)

(55.3-56.2%)

head & neck

both

all 15-99

38.4%

44.1%

50.3%

50.7%

(ICD10 C01-C06,C09-C13)

(unstandardized)

(34.4-42.3%)

(40.4-47.8%)

(46.1-54.4%)

(46.1-55.0%)

head & neck

both

all 15-99

35.9%

40.5%

44.3%

(ICD10 C01-C06,C09-C13)

(age-standardized)#

(27.6-44.5%)

(32.5-48.7%)

(35.6-52.9%)

(34.4-54.2%)

Five-year relative survival (with 95% confidence interval)

EUROCARE-4

Cancer type

Sex

Age at diagnosis

1994-97

1998-2002

2003-2007

2007-2009

##2000-2002

(EUROCARE definition)

cohort

*hybrid

Ireland

Europe average

oesophagus

both

all 15-99

12.5%

13.1%

15.8%

14.9%

(ICD10 C15)

(unstandardized)

(10.3-14.8%)

(11.1-15.1%)

(13.3-18.6%)

(12.3-17.6%)

oesophagus

both

all 15-99

12.9%

13.2%

16.2%

15.5%

(ICD10 C15)

(age-standardized)#

(8.4-18.4%)

(9.1-18.0%)

(10.9-22.4%)

(10.0-22.0%)

stomach

both

all 15-99

17.2%

17.3%

23.9%

25.2%

(ICD10 C16)

(unstandardized)

(15.2-19.2%)

(15.4-19.1%)

(21.4-26.4%)

(22.3-28.0%)

stomach

both

all 15-99

17.4%

17.6%

23.4%

24.1%

18.8%

24.9%

(ICD10 C16)

(age-standardized)#

(13.2-22.2%)

(13.6-21.8%)

(18.4-28.8%)

(18.1-30.5%)

(16.5-21.5%)

(23.7-26.2%)

colorectal

both

all 15-99

49.0%

52.5%

57.6%

58.2%

(ICD10 C18-C21)

(unstandardized)

(47.5-50.5%)

(51.2-53.8%)

(56.0-59.1%)

(56.5-59.8%)

colorectal

both

all 15-99

48.9%

52.4%

57.0%

57.2%

54.3%

56.2%

(ICD10 C18-C21)

(age-standardized)#

(45.6-52.1%)

(49.6-55.1%)

(53.7-60.2%)

(53.7-60.5%)

(52.6-56.0%)

(55.3-57.2%)

colon

both

all 15-99

50.5%

53.1%

57.7%

58.2%

(ICD10 C18)

(unstandardized)

(48.6-52.4%)

(51.4-54.8%)

(55.7-59.6%)

(56.1-60.2%)

colon

both

all 15-99

50.2%

53.2%

57.6%

(ICD10 C18)

(age-standardized)#

(64.1-54.2%)

(49.5-56.7%)

(53.4-71.7%)

(53.1-61.8%)

Five-year relative survival (with 95% confidence interval)

EUROCARE-4

Cancer type

Sex

Age at diagnosis

1994-97

1998-2002

2003-2007

2007-2009

##2000-2002

(EUROCARE definition)

cohort

*hybrid

Ireland

Europe average

rectum/anus

both

all 15-99

46.5%

51.6%

57.4%

58.2%

(ICD10 C19-C21)

(unstandardized)

(44.0-48.8%)

(49.5-53.6%)

(54.8-59.8%)

(55.5-60.7%)

rectum/anus

both

all 15-99

46.4%

50.8%

55.8%

56.6%

(ICD10 C19-C21)

(age-standardized)#

(41.0-51.6%)

(46.3-55.0%)

(50.5-61.0%)

(50.9-62.0%)

pancreas

both

all 15-99

5.5%

5.8%

6.2%

(ICD10 C25)

(unstandardized)

(4.1-7.1%)

(4.5-7.1%)

(4.6-8.0%)

(4.7-8.1%)

pancreas

both

all 15-99

5.7%

6.5%

7.3%

8.1%

(ICD10 C25)

(age-standardized)#

(2.9-10.1%)

(3.8-10.2%)

(4.0-11.8%)

(4.5-12.9%)

liver

both

all 15-99

4.3%

10.8%

12.9%

12.8%

(ICD10 C22)

(unstandardized)

(2.0-8.0%)

(7.7-14.4%)

(9.4-17.0%)

(9.3-16.8%)

liver

both

all 15-99

11.0%

13.3%

13.4%

(ICD10 C22)

(age-standardized)#

(5.1-19.3%)

(6.6-22.6%)

(6.3-23.4%)

larynx

both

all 15-99

63.4%

58.1%

57.9%

61.1%

(ICD10 C32)

(unstandardized)

(57.4-69.0%)

(53.1-62.9%)

(51.8-63.7%)

(55.1-66.7%)

larynx

both

all 15-99

63.4%

54.8%

56.2%

57.1%

(ICD10 C32)

(age-standardized)#

(48.1-75.4%)

(43.9-64.6%)

(42.7-68.1%)

(42.8-68.9%)

Five-year relative survival (with 95% confidence interval)

EUROCARE-4

Cancer type

Sex

Age at diagnosis

1994-97

1998-2002

2003-2007

2007-2009

##2000-2002

(EUROCARE definition)

cohort

*hybrid

Ireland

Europe average

lung & trachea

both

all 15-99

8.6%

9.4%

11.7%

12.2%

(ICD10 C33-C34)

(unstandardized)

(7.8-9.5%)

(8.7-10.1%)

(10.7-12.7%)

(11.1-13.2%)

lung & trachea

both

all 15-99

9.3%

10.2%

12.7%

13.3%

10.9%

(ICD10 C33-C34)

(age-standardized)#

(7.3-11.6%)

(8.5-12.2%)

(10.5-15.2%)

(10.7-16.0%)

(9.8-12.2%)

(10.5-11.4%)

bone & cartilage

both

all 15-99

50.0%

57.4%

64.4%

62.5%

(ICD10 C40-C41)

(unstandardized)

(39.4-60.0%)

(47.7-66.1%)

(52.9-74.2%)

(50.2-73.1%)

bone & cartilage

both

all 20-99

49.8%

53.5%

67.0%

69.6%

(ICD10 C40-C41)

(age-standardized)#

melanoma of skin

both

all 15-99

83.6%

85.4%

86.6%

86.5%

(ICD10 C43)

(unstandardized)

(80.8-86.1%)

(83.2-87.4%)

(84.1-88.8%)

(84.0-88.6%)

melanoma of skin

both

all 15-99

82.9%

85.3%

86.0%

85.9%

86.1%

(ICD10 C43)

(age-standardized)#

(76.9-88.1%)

(80.5-89.4%)

(80.5-90.5%)

(80.7-90.4%)

(83.1-88.8%)

(84.3-88.0%)

soft tissue

both

all 15-99

53.1%

59.2%

63.3%

64.9%

(ICD10 C47 & C49)

(unstandardized)

(46.4-59.5%)

(53.2-64.8%)

(56.1-70.0%)

(57.2-71.8%)

soft tissue

both

all 15-99

52.6%

58.1%

63.3%

64.1%

60.2%

61.2%

(ICD10 C47 & C49)

(age-standardized)#

(38.2-66.0%)

(45.2-69.7%)

(48.5-75.6%)

(47.5-77.5%)

(52.4-69.3%)

(58.3-64.2%)

Five-year relative survival (with 95% confidence interval)

EUROCARE-4

Cancer type

Sex

Age at diagnosis

1994-97

1998-2002

2003-2007

2007-2009

##2000-2002

(EUROCARE definition)

cohort

*hybrid

Ireland

Europe average

breast (female)

female

all 15-99

73.8%

79.8%

85.0%

85.4%

(ICD10 C50)

(unstandardized)

(72.5-75.1%)

(78.8-80.8%)

(83.8-86.1%)

(84.2-86.5%)

breast

female

all 15-99

71.7%

76.8%

81.8%

82.1%

76.2%

79.0%

(ICD10 C50)

(age-standardized)#

(68.3-74.9%)

(74.1-79.2%)

(78.6-84.7%)

(79.0-84.9%)

(74.3-78.2%)

(78.1-80.0%)

cervix uteri

female

all 15-99

61.3%

68.5%

66.2%

68.5%

(ICD10 C53)

(unstandardized)

(57.3-65.0%)

(65.1-71.6%)

(62.2-69.8%)

(64.5-72.1%)

cervix uteri

female

all 15-99

53.6%

63.2%

55.8%

56.8%

63.8%

60.4%

(ICD10 C53)

(age-standardized)#

(43.4-63.8%)

(54.3-71.3%)

(45.6-66.2%)

(47.1-66.6%)

(58.8-69.3%)

(57.7-63.2%)

corpus uteri

female

all 15-99

77.6%

78.3%

77.3%

78.9%

(ICD10 C54)

(unstandardized)

(73.7-81.1%)

(75.1-81.2%)

(73.6-80.6%)

(75.2-82.2%)

corpus uteri

female

all 15-99

73.5%

75.6%

72.5%

73.8%

77.0%

78.0%

(ICD10 C54)

(age-standardized)#

(64.3-81.0%)

(68.4-81.9%)

(64.0-79.9%)

(65.0-81.1%)

(72.3-81.9%)

(76.2-79.9%)

ovary & uterine adnexa

female

all 15-99

36.1%

33.1%

38.9%

38.8%

(ICD10 C56 & C57.0-57.7)~

(unstandardized)

(33.0-39.2%)

(30.4-35.7%)

(35.6-42.1%)

(35.3-42.2%)

ovary & uterine adnexa

female

all 15-99

31.4%

28.4%

31.3%

(ICD10 C56 & C57.0-57.7)

(age-standardized)#

(25.1-38%)

(23.3-33.9%)

(25.4-37.4%)

(25.2-37.8%)

Five-year relative survival (with 95% confidence interval)

EUROCARE-4

Cancer type

Sex

Age at diagnosis

1994-97

1998-2002

2003-2007

2007-2009

##2000-2002

(EUROCARE definition)

cohort

*hybrid

Ireland

Europe average

prostate

male

all 15-99

65.0%

80.7%

92.8%

93.2%

(ICD10 C61)

(unstandardized)

(62.8-67.1%)

(79.2-82.0%)

(91.5-94.0%)

(91.9-94.4%)

prostate

male

all 15-99

65.2%

80.5%

89.9%

90.4%

77.5%

(ICD10 C61)

(age-standardized)#

(59.6-70.4%)

(77.2-83.5%)

(86.7-92.8%)

(87.3-93.3%)

[sparse data]

(76.5-78.6%)

testis

male

all 15-99

89.2%

95.5%

97.0%

97.7%

(ICD10 C62)

(unstandardized)

(85.2-92.3%)

(93.2-97.0%)

(95.0-98.3%)

(95.8-98.9%)

testis

male

15-64

87.9%

94.9%

97.0%

97.4%

97.3%

(ICD10 C62)

(age-standardized)#

[sparse data]

(96.4-98.2%)

kidney & related

both

all 15-99

50.7%

52.0%

57.5%

60.1%

(ICD10 C64-66 & C68)

(unstandardized)

(46.8-54.4%)

(48.9-55.0%)

(54.0-60.8%)

(56.5-63.5%)

kidney & related

both

all 15-99

47.3%

48.6%

53.7%

56.4%

54.1%

55.7%

(ICD10 C64-66 & C68)

(age-standardized)#

(39.4-54.9%)

(42.2-54.8%)

(46.8-60.4%)

(46.9-60.8%)

(47.8-61.2%)

(53.6-58.0%)

bladder

both

all 15-99

69.7%

71.0%

69.4%

68.0%

(ICD10 C67)

(unstandardized)

(66.5-72.7%)

(68.1-73.7%)

(65.9-72.7%)

(64.4-71.4%)

bladder

both

all 15-99

70.1%

71.2%

69.2%

68.6%

(ICD10 C67)

(age-standardized)#

(63.8-75.7%)

(65.6-76.1%)

(61.9-75.5%)

(61.1-75.0%)

Five-year relative survival (with 95% confidence interval)

EUROCARE-4

Cancer type

Sex

Age at diagnosis

1994-97

1998-2002

2003-2007

2007-2009

##2000-2002

(EUROCARE definition)

cohort

*hybrid

Ireland

Europe average

brain

both

all 15-99

18.7%

21.6%

19.1%

18.5%

(ICD10 C71)

(unstandardized)

(16.0-21.6%)

(19.1-24.1%)

(16.3-22%)

(15.6-21.5%)

brain

both

all 15-99

19.1%

22.4%

21.4%

21.3%

(ICD10 C71)

(age-standardized)#

(14.5-24.7%)

(18.3-27.2%)

(16.3-27.4%)

(15.9-27.6%)

thyroid

both

all 15-99

73.9%

82.1%

84.7%

85.7%

(ICD10 C73)

(unstandardized)

(66.7-80.3%)

(76.9-86.6%)

(78.7-89.4%)

(80.5-90.0%)

thyroid

both

all 15-99

70.3%

73.4%

76.1%

77.2%

75.8%

83.2%

(ICD10 C73)

(age-standardized)#

(57.9-80.7%)

(62.9-82.4%)

(60.4-87.0%)

(63.0-87.1%)

(69.3-82.9%)

(80.9-85.6%)

Hodgkin lymphoma

both

all 15-99

78.6%

81.2%

87.5%

88.3%

(ICD10 C81)

(unstandardized)

(72.9-83.3%)

(76.6-85.0%)

(83.2-91.0%)

(83.4-92.1%)

Hodgkin lymphoma

both

all 15-99

72.1%

75.4%

84.1%

84.3%

77.2%

81.4%

(ICD10 C81)

(age-standardized)#

(72.0-82.7%)

(78.9-84.1%)

non-Hodgkin lymphoma

both

all 15-99

52.9%

57.2%

67.7%

68.2%

(ICD10 C82-C85 & C96)

(unstandardized)

(49.8-55.8%)

(54.7-59.5%)

(64.9-70.3%)

(65.3-70.9%)

non-Hodgkin lymphoma

both

all 15-99

47.6%

51.2%

61.1%

61.6%

52.0%

54.6%

(ICD10 C82-C85 & C96)

(age-standardized)#

(41.2-53.9%)

(46.0-56.2%)

(55.3-66.7%)

(55.5-67.3%)

(47.5-56.9%)

(52.7-56.6%)

Five-year relative survival (with 95% confidence interval)

EUROCARE-4

Cancer type

Sex

Age at diagnosis

1994-97

1998-2002

2003-2007

2007-2009

##2000-2002

(EUROCARE definition)

cohort

*hybrid

Ireland

Europe average

multiple myeloma

both

all 15-99

25.9%

28.9%

41.9%

42.9%

(ICD10 C90)

(unstandardized)

(22.1-29.8%)

(25.5-32.3%)

(37.1-46.7%)

(38.1-47.7%)

multiple myeloma

both

all 15-99

27.6%

29.6%

42.7%

44.2%

(ICD10 C90)

(age-standardized)#

(18.9-36.5%)

(22.6-36.6%)

(32.8-51.8%)

(33.4-53.1%)

leukaemia

both

all 15-99

47.3%

53.3%

59.4%

59.8%

(ICD10 C91-C95)

(unstandardized)

(43.8-50.6%)

(50.4-56.0%)

(56.0-62.7%)

(56.2-63.1%)

leukaemia

both

all 15-99

46.6%

51.7%

56.2%

57.2%

(ICD10 C91-C95)

(age-standardized)#

(39.3-53.7%)

(45.6-57.4%)

(49.2-62.8%)

(49.8-63.9%)

Footnotes:

*Hybrid estimate for 2007-2009 is the most up-to-date survival estimate and is based on follow-up of all cases alive at any point during this period,
supplemented by follow-up 2005-2009 for cases diagnosed in 2005-2006 (to provide more reliable estimation of the first two years of survival).
In practice, the hybrid estimate for 2007-2009 is similar to the most recent (incomplete) cohort, i.e. cases diagnosed 2003-2007, reflecting substantial overlap of data.

# Age-standardized figures use the standard patient population proposed for this cancer by:
Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316.

## For comparison, the age-standardized average survival (2000-2002) is quoted for countries (including Ireland) that participated in the EUROCARE-4 'period' analysis:
Verdecchia A., Francisci S., Brenner H., et al. 2007. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796.

Exclusions (as in EUROCARE except for bladder):
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient
(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour (both INCLUDED for bladder by EUROCARE but not here).

~ Definition of cancer of the ovary and uterine adnexa used here & in EUROCARE-4 = ICD10 codes C56 and C57.0-C57.7
with the exception of 'borderline' morphologies (not considered malignant in ICDO3).

- = insufficient data

© National Cancer Registry Ireland 2011 (October 2011) Relative survival statistics for Irish cancer patients